Goldman's "neutral" call on the market had a dramatic headline but the market had zero reaction—and with good reason, says floor trader Kenny Polcari.» Read More
Brad Hintz, Sanford C. Bernstein Equity research analyst and former Lehman Brothers CFO, discusses earnings for big banks.
Doug Freedman, RBC Capital Markets, explains why Intel's doubling down of investment in the tablet market is reason to move on to Marvell.
David Strasser, Janney Capital Markets managing director, looks at Best Buy in the most "most aggressive promotional environment he has seen since 1995."
Is there a reason to avoid Facebook? Aaron Kessler, Raymond James, and Brian Evans, AdvisorShares, debate the play on the social media giant. Kessler recently increased his price target to $63 from $60.
Where will stocks close the day? The market's next move, with CNBC's Jackie DeAngelis and the Futures Now Traders.
David Seaburg of Cowen & Co. says hedge funds are too underweight the technology sector, and are likely to rush in this year, with CNBC's Jackie DeAngelis and the Futures Now Traders.
Tech is outperforming so far this year, and hedge funds may be looking to reallocate into tech, with Cowen's David Seaburg, CNBC's Jackie DeAngelis and the Futures Now Traders.
Michael Dudas of Sterne Agee explains why gold could mount a minor comeback in 2014, with CNBC's Jackie DeAngelis and the Futures Now Traders.
Can gold keep rising in 2014? Michael Dudas from Sterne Agee thinks so. With CNBC's Jackie DeAngelis and the Futures Now Traders, Jim Iuorio at the CME and Anthony Grisanti at the Nymex.
FMHR traders Jon Najarian and Steve Weiss debate the play on Yahoo. Dr. J says Alibaba will drive value. Weiss says everything that is good with Yahoo was good before Mayer got there.
United Health sells of despite beating Q4 estimates, and Solar City shares rally. The FMHR traders share their strategies to playing the stocks.
Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.
Cramer shares six stocks to watch, and reveals them in under 60 seconds, including the play on SeaWorld, AOL and Facebook.
Jim Cramer says SolarCity is a "must" have company, especially under the leadership of Elon Musk.
Peter Wilmshurst, EVP & Portfolio Manager, Templeton Global Equity Group talks about his investment strategy and the growing importance of China among other stock markets.
Most stocks that ended 2013 in negative territory did so for a reason. However, sometimes those reasons change.
Edwards Lifesciences is the medical device maker focused on heart-related products. Michael Mussallem, chairman and CEO, discusses issues with Medtronic and says he knew competitors would come into market eventually.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
People are often surprised Jim Cramer does this in an attempt to get ahead of a big rally.
Mad Money host Jim Cramer discusses how technicals may be able to give you a different view on the world's most valuable companies.